Project Cure CRC
Request for Proposals
Project Cure CRC has announced a rolling Request for Proposals (RFP), making available tens of millions of dollars to academic and industry researchers whose work aims to expedite colorectal cancer research to a curable science. Download the RFP for details and submit your proposal at ProposalCentral.
Hope for today's patients
With bold and urgent action, Project Cure CRC seeks to cultivate breakthroughs in colorectal cancer diagnosis, treatment, metastasis, and survivorship. The project will ignite innovative treatments to end colorectal cancer now.
Funded research
Raghu Kalluri, MD, PhD
Dr. Kalluri of MD Anderson Cancer Center aims to develop urgently needed therapeutic options for the 96% of colorectal cancer patients with microsatellite stable (MSS) disease.
H. Charles Manning, PhD
H. Charles Manning, PhD, a professor at MD Anderson Cancer Center, will lead a collaborative effort to discover the first theranostic pair for imaging and therapy for patients with CRC.
Peter Lee, MD
Dr. Peter Lee of City of Hope will pursue a novel combination immunotherapy to treat metastatic MSS colorectal cancer, which does not respond well to current treatments.
Kevin Van der Jeught, PhD
Kevin Van Der Jeught, PhD, of the University of Miami, seeks to improve intratumoral mRNA vaccination strategies by targeting immune checkpoints to enhance anti-tumor immune responses.
Ekaterina Dadachova, PhD
Ekaterina Dadachova, PhD, of The University of Saskatchewan will investigate combining targeted radiation with immunotherapies for a novel and synergistic approach to treat advanced colorectal cancer, improving clinical outcomes.
Yekaterina Y. Zaytseva, PhD
Yekaterina Y. Zaytseva, PhD, of the University of Kentucky, will investigate new drug combinations to kill CRC cells with a BRAF mutation. These cells currently have a low response rate to existing treatments.
Ashiq Masood, MD
Dr. Masood of Indiana University is studying ProAgio, a new protein that targets cells aiding cancer's survival. This approach could improve therapies for tough-to-treat tumors.
Caterina Suelzu, PhD
Dr. Suelzu of Anglia Ruskin University will investigate how fat tissue impacts the growth and spread of colorectal cancer, especially in people with obesity.
Julia Carnevale, MD
Dr. Carnevale of UCSF will use cutting-edge technology to target multiple genes at once, seeking to uncover weaknesses in cancer cells and boost the body’s immune response.
David Robbins, PhD
Dr. Robbins of Georgetown University aims to target and stop the circulating tumor cells responsible for forming metastatic tumors. Success could improve mCRC survival rates.
Cure CRC Summit
In December 2023, the Cure CRC Summit welcomed more than 100 prominent scientists to foster partnerships that will challenge the status quo of colorectal therapies and discover new trajectories toward a cure.
Project Cure CRC Co-ChairsMichael Sapienza Alliance Project LeadDavid Fenstermacher, PhD | Scientific Co-ChairsJohn Marshall, MD Scott Kopetz, MD, PhD, FACP Christopher Lieu, MD Patient Advocate Co-ChairJohn Woerner |
Grant Review CommitteeJ. Randolph Hecht, MD Scott Kopetz, MD, PhD, FACP Christopher Lieu, MD | John Marshall, MD Alan P. Venook, MD |
Support the project
The Colorectal Cancer Alliance invites the public, corporations, foundations, and philanthropic individuals to join us by contributing to Project Cure CRC.
Top resources
Be heard this November: The Cancer Promise
Learn about The Cancer Promise initiative and how political candidates can pledge to support cancer research, prevention, and care policies. Make your voice heard this election.
Alliance supports the Clinical Trials Modernization Act
This bipartisan legislation aims to improve participation in clinical trials by addressing major barriers such as non-medical expenses, trial location accessibility, diverse participation, and financial implications for patients.
23andMe and the Alliance team up on cancer research
The collaboration aims to raise awareness, encourage screening, and help people better understand their risks.